tacrolimus + sirolimus

Tacrolimus + sirolimus is a combination of two immunosuppressive agents used primarily to prevent organ rejection in transplant recipients. Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by inhibiting the phosphatase activity of calcineurin, thereby reducing interleukin-2 production. Sirolimus, also known as rapamycin, binds to FKBP12 and inhibits the mammalian target of rapamycin (mTOR), blocking cell cycle progression and T-cell proliferation in response to interleukin signals. The combination leverages complementary mechanisms—tacrolimus reduces cytokine gene activation while sirolimus blocks downstream cell cycle entry—resulting in synergistic immunosuppression. This regimen has been studied for kidney and lung transplantation, showing efficacy comparable or superior to other regimens such as mycophenolate mofetil plus tacrolimus, with potential benefits for long-term graft survival and reduced nephrotoxicity when using lower doses[1][2][3][5][7].

Brand names

Prograf (tacrolimus)Rapamune (sirolimus)

Other names

FK506 + rapamycin